Skip to main content
SpringerLink
Log in

A Case for Prodrugs

  • Chapter
Prodrugs

Part of the book series: Biotechnology: Pharmaceutical Aspects ((PHARMASP,volume V))

Abstract

A prodrug is a bioreversible derivative of a molecule that has some barrier to its utility as an effective drug. The prodrug concept is illustrated by Scheme 1.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 309.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 399.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 549.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Aguiar AJ, Krc J Jr, Kinkel AW, and Samyn JC. Effect of Polmorphism on the Absorption of Chloramphenicol from Chloramphenicol Palmitate. J Pharm Sci 1967; 56:847–853

    Article  PubMed  CAS  Google Scholar 

  • Albert A. Chemical Aspects of Selective Toxicity. Nature 1958; 182:421–423

    Article  PubMed  CAS  Google Scholar 

  • Albert A. Selective Toxicity: The Physico-Chemical Basis of Therapy. 7th edition. New York, NY: Chapman and Hall; 1985. pp. 97–109, 208–214

    Google Scholar 

  • Andersgaard H, Finholt P, Gjermundsen R, and Hoyland T. Rate Studies on Dissolution and Enzymatic Hydrolysis of Chloramphenicol Palmitate, Acta Pharm Suec 1974; 11:239–248

    PubMed  CAS  Google Scholar 

  • Anon. Lexiva (fosamprenavir calcium) tablets. Prescribing information. GlaxoSmithKline and Vertex. 2003; 1–36

    Google Scholar 

  • Balzarini J, Naesens L, Herdewijn P, Rosenberg I, Holy A, Pauwels R, Baba M, Johns DG, and De Clercq E. Marked in vivo Antiretrovirus Activity of 9-(2-Phosphonylmethoxyethyl) Adenine, a Selective Anti-human Immunodeficiency Virus Agent. Proc Natl Acad Sci USA 1989; 86:332–336.

    Article  PubMed  CAS  Google Scholar 

  • Bentley A, Butters M, Green SP, Learmonth WJ, MacRae JA, Morland MC, O’Connor G, and Skuse J. The Discovery and Process Development of a Commercial Route to the Water Soluble Prodrug, Fosfluconazole. Org Process Res Dev 2002; 6:109–112

    Article  CAS  Google Scholar 

  • Bernardelli P, Gaudilliere B, and Vergne F. To Market, To Market—2001. In: Doherty AM. Annual Reports in Medicinal Chemistry. San Diego: Academic Press; 2002 Vol. 37:257–277

    Google Scholar 

  • Bey P. Prodrugs Activees Specifiquement par le Recepteur-cible: Inhibition Enzymatique du Type kCAT. Sci Techn Pharm 1978; 7:171–1176

    CAS  Google Scholar 

  • Bundgaard H. Design of Prodrugs. Amsterdam: Elsevier; 1985

    Google Scholar 

  • Bundgaard H. (Ed), Themed issue. Prodrugs for Improved Drug Delivery. Adv Drug Deliv Rev 1989; 3:1–154

    Google Scholar 

  • Burke JT. Wargin WA. Sherertz RJ. Sanders KL. Blum MR. and Sarubbi FA. Pharmacokinetics of Intravenous Chloramphenicol Succinate in Adult Patients with Normal Renal and Hepatic Function. J Pharmacokinet Biopharm 1982; 10:601–614

    Article  PubMed  CAS  Google Scholar 

  • Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, Hellmann NS, Safrin S, and Kahn JO. Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-(R)-(phosphonomethoxy)propyl] Adenine, a Novel Anti-human Immunodeficiency Virus (HIV) Therapy, in HIVInfected Adults. Antimicrob Agents Chemother 1998; 42:2380–2384

    PubMed  CAS  Google Scholar 

  • Dellamonica, P. Cefuroxime Axetil. Int J Antimicrob Agents 1994; 4:23–36, and references therein

    Article  PubMed  CAS  Google Scholar 

  • De Clercq E. Acyclic Nucleoside Phosphonates: A New Dimension to the Chemotherapy of DNA Virus and Retrovirus Infections. J Med Microbiol 1998; 47:1–3

    Article  PubMed  Google Scholar 

  • Denny WA. Prodrug Strategies in Cancer Therapy. Eur J Med Chem. 2001; 36:577–595

    Article  PubMed  CAS  Google Scholar 

  • Denny WA. Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy). J Biomed Biotech 2003:48–70

    Google Scholar 

  • Doherty AM. To Market, To Market—2002. Ann Rep Med Chem 2003; 38:347–374

    Google Scholar 

  • Ehrlich P. Collected Studies on Immunity, New York: John Wiley and Sons; 1906. 586p

    Google Scholar 

  • Ehrlich P. Partial Cell Functions, Nobel Lecture December 11, 1908

    Google Scholar 

  • Elger W, Schwarz S, Hedden A, Reddersen G, and Schneider B. Sulfamates of Various Estrogens are Prodrugs with Increased Systemic and Reduced Hepatic Estrogenicity at Oral Application. J Steroid Biochem Mol Biol 1995; 55:395–403

    Article  PubMed  CAS  Google Scholar 

  • Elger W, Palme HJ, and Schwarz S. Novel Oestrogen Aulfamates: A New Approach to Oral Hormone Therapy. Expert Opin Investig Drugs 1998; 7:575–589

    Article  PubMed  CAS  Google Scholar 

  • Fechner J, Ihmsen H, Hatterscheid D, Schiessi C, Vornov JJ, Burak E, Schwilden H, and Schuttler J. Pharmacokinetics and Clinical Pharmacodynamics of the New Propofol Prodrug GPI 15715 in Volunteers. Anesthesiol 2003; 99:303–313

    Article  CAS  Google Scholar 

  • Ferres H. Pro-Drugs of,-Lactam Antibiotics. Drugs of Today 1983; 19:499–538

    CAS  Google Scholar 

  • Fleisher D, Stewart B, and Amidon GL. Design of Prodrugs for Improved Gastrointestinal Absorption by Intestinal Enzyme Targeting. Methods Enzymol 1985; 112:360–381

    PubMed  CAS  Google Scholar 

  • Glazko AJ, Edgerton WH, Dill WA, and Lenz WR. Chloromycetin Palmitate—A Synthetic Ester of Chloromycetin. Antibiot Chemother 1952; 2:234–241

    CAS  Google Scholar 

  • Glazko AJ, Carnes HE, Kazenk A, Wolf LM, and Reutner TF. Succinic Acid Esters of Chloramphenicol. Antibiot Annu 1957–1958; 792–802

    Google Scholar 

  • Glazko AJ, Dill WA, Kazenko A, Wolf LM, and Carnes HE. Physical Factors Affecting the Rate of Absorption of Chloramphenicol Esters. Antibiot Chemother 1958; 8:516–527

    CAS  Google Scholar 

  • Gustafsson D. Oral Direct Thrombin Inhibitors in Clinical Development. J Intern Med 2003; 254:322–334

    Article  PubMed  CAS  Google Scholar 

  • Gustafsson D, Nystrom J, Carlsson S, Bredberg U, Eriksson U, Gyzander E, Elg M, Antonsson T, Hoffmann K, Ungell A, Sorensen H, Nagard S, Abrahamsson A, and Bylund R. The Direct Thrombin Inhibitor Melagatran and Its Oral Prodrug H 376/95: Intestinal Absorption Properties, Biochemical and Pharmacodynamic Effects. Thromb Res 2001; 101:171–181

    Article  PubMed  CAS  Google Scholar 

  • Hale MR, Tung RD, Baker CT, and Spaltenstein A. Prodrugs of Aspartyl Protease Inhibitors. US Patent #6,436,989, August 20, 2002

    Google Scholar 

  • Harper NJ. Drug Latentiation. J Med Pharm Chem 1959; 1:467–500

    Article  PubMed  CAS  Google Scholar 

  • Harper NJ. Drug Latentiation. Prog Drug Res 1962; 4:221–294

    CAS  Google Scholar 

  • Heimbach T, Oh DM, Li LY, Forsberg M, Savolainen J, Leppanen J, Matsunaga Y, Flynn G, and Fleischer D. Absorption Rate Limit Considerations for Oral Phosphate Prodrugs. Pharm Res 2003; 20:848–856

    Article  PubMed  CAS  Google Scholar 

  • Higuchi T, and Stella V. Pro-drugs as Novel Drug Delivery Systems. Washington DC. ACS Symposium Series #14, American Chemical Society; 1975

    Google Scholar 

  • Horspool KR, Lipinski CA. Enabling Strategies: Advancing New Drug Delivery Concepts to Gain the Lead. Drug Deliv Tech 2003; 3:34–46

    CAS  Google Scholar 

  • Im WB, Sih JC, Blakeman DP, and McGarth JP. Omeprazole, a Specific Inhibitor of Gastric (H+-K+)-ATPase, is a H+-Activated Oxidizing Agent of Sulfhydryl Groups. J Biol Chem 1985; 260:4591–4597

    PubMed  CAS  Google Scholar 

  • Johnson P. Pro-drugs and First-Pass Effects. Chem Ind 1980; June 7:443–447

    Google Scholar 

  • Jusko WJ. Guidelines for Collection and Analysis of Pharmacokinetic Data. In: Evans WE, Schentag JJ, and Jusko WJ. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, 2nd edition. Spokane, WA: Applied Therapeutics Inc.; 1986:9–54

    Google Scholar 

  • Lin JH, and Yamazaki M. Clinical Relevance of P-Glycoprotein in Drug Therapy. Drug Metab Rev 2003a; 35:417–454

    Article  PubMed  CAS  Google Scholar 

  • Lin JH, and Yamazaki M. Role of P-Glycoprotein in Pharmacokinetics: Clinical Implications. Clin Pharmacokinet. 2003b; 42:59–98

    Article  PubMed  CAS  Google Scholar 

  • Lindberg P, Nordberg P, Alminger T, Brrandstrom A, Wallmark B. The Mechanism of Action of the Gastric Acid Secretion Inhibitor Omeprazole. J Med Chem 1986; 29:1327–1329

    Article  PubMed  CAS  Google Scholar 

  • Lipinski CA. Drug-Like Properties and the Causes of Poor Solubility and Poor Permeability. J Pharmacol Toxicol Meth 2000; 44:235–249

    Article  CAS  Google Scholar 

  • Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ. Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings. Adv Drug Deliv Rev 1997; 23:3–25

    Article  CAS  Google Scholar 

  • Nahata MC. and Powell DA. Bioavailability and Clearance of Chloramphenicol after Intravenous Chloramphenicol Succinate. Clin Pharmacol Ther 1981; 30:368–372

    Article  PubMed  CAS  Google Scholar 

  • Pereillo J-M, Maftouh M, Andrieu A, Uzabiaga M-F, Fedeli O, Savi P, Pascal M, Herbert J-M, Maffrand J-P, and Picard C. Structure and Stereochemistry of the Active Metabolite of Clopidogrel. Drug Metab Dispos 2002; 30:1288–1295

    Article  PubMed  CAS  Google Scholar 

  • Plamondon L, Grenier L, Adams J, and Gupta SL. Formulation of Boronic Acid Compounds. US Patent #6,699,835, issued March 2, 2004

    Google Scholar 

  • Richter T, Murdter TE, Heinkele G, Pleiss J, Tatzel S, Schwab M, Eichelbaum M, and Zanger UM. Potent Mechanism-Based Inhibition of Human CYP2B6 by Clopidogrel and Ticlopidine. J Pharmacol Exp Ther 2004; 308:189–97.

    Article  PubMed  CAS  Google Scholar 

  • Roche EB. Design of Biopharmaceutical Properties Through Prodrugs and Analogs. Washington, DC: American Pharmaceutical Association; 1977. 455p

    Google Scholar 

  • Rosenberg IH. Intestinal Absorption of Folate. In: Johnson LR. Physiology of the Gastrointestinal Tract. New York: Raven Press; 1981: Vol. 2:1221–1230

    Google Scholar 

  • Savi P, Labouret C, Guette F, Lupker J, and Herbert JM. P2Y12, A New Platelet Receptor, Target for Clopidogrel. Biochem Biophys Res Comm 2001; 283:379–383

    Article  PubMed  CAS  Google Scholar 

  • Schywalsky M, Ihmsen H, Tzabazis A, Fechner J. Burak E. Vornov J, and Schwilden H. Pharmacokinetics and Pharmacodynamics of the New Propofol Prodrug GPI 15715 in Rats. Eur J Anesthesiol 2003; 20:182–190

    Article  CAS  Google Scholar 

  • Seddon B, Kelland LR, and Workman P. Bioreductive Prodrugs for Cancer Therapy. Methods Mol Med 2004; 90:515–542

    PubMed  CAS  Google Scholar 

  • Shaw JP, Sueoko CM, Oliyai R, Lee WA, Arimilli MN, Kim CU, and Cundy KC. Metabolism and Pharmacokinetics of Novel Oral Prodrugs of 9-[(R)-2-(phosphonomethoxy)propyl]adenine (PMPA) in Dogs. Pharm Res 1997; 14:1824–1829

    Article  PubMed  CAS  Google Scholar 

  • Sinkula AA. Prodrug Approach in Drug Design. Ann Rep Med Chem 1975; 10:306–316

    Article  CAS  Google Scholar 

  • Sinkula AA, and Yalkowsky SJ. Rationale for the Design of Biologically Reversible Derivatives: Prodrugs. J Pharm Sci 1975; 64:181–210

    Article  PubMed  CAS  Google Scholar 

  • Sloan KB. Prodrugs: Topical and Ocular Drug Delivery. New York: Marcel Dekker Inc; 1992. 313p

    Google Scholar 

  • Stella VJ. Themed issue. Low Molecular Weight Prodrugs. Adv Drug Deliv Rev 1996a; 19:111–330

    Article  Google Scholar 

  • Stella VJ. Themed issue. Preface. Adv Drug Deliv Rev 1996b; 19:111–114

    Article  Google Scholar 

  • Stella VJ. Themed issue. A Case for Prodrugs, Fosphenytoin, Adv Drug Deliv Rev 1996c; 19:311–330

    Article  CAS  Google Scholar 

  • Stella VJ. Prodrugs as Therapeutics. Expert Opin 2004; 14:YY–ZZ

    Google Scholar 

  • Stella VJ, Zygmunt JJ, Georg IG, and Safadi MS. Water Soluble Prodrugs of Hindered Alcohols. US Patent #6,204,257, March 20, 2001

    Google Scholar 

  • Svensson LA, and Tunek A. The Design and Bioactivation of Presystemically Stable Prodrugs. Drug Metab Rev 1988; 19:165–194

    Article  PubMed  CAS  Google Scholar 

  • Testa B, Prodrug Research: Futile or Fertile. Biochem Pharmacol. 2004; 68:2097–2106

    Article  PubMed  CAS  Google Scholar 

  • Testa B, and Mayer JM. Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry and Enzymology. Weinheim; Federal Republic of Germany; Wiley-VCH; 2003. 780p

    Google Scholar 

  • Tung RD, Murcko MA, and Bhisetti GR. Sulfonamide Inhibitors of Aspartyl Protease. US Patent #5,585,397, December 17, 1996

    Google Scholar 

  • Ueda Y, Matiskella JD, Golik J, Connolly TP, Hudyma TW, Ventaesh S, Dali M, Kang S-H, Barbour N, Tejwani R, Varia S, Knipe J, Zheng M, Mathew M, Mosure K, Clark J, Lamb L, Medin I, Gao Q, Huang S, Chen C-P, and Bronson JJ. Phosphonooxymethyl Prodrugs of the Broad Spectrum Antifungal Azole, Ravuconazole: Synthesis and Biological Properties. Bioorg Med Chem Lett 2003; 13:3669–3672

    Article  PubMed  CAS  Google Scholar 

  • Ulm EH. Enalaril Maleate (MK-421), a Potent Nonsulfhydryl Angiotensin-Converting Enzyme Inhibitor: Absorption, Disposition, and Metabolism in Man. Drug Metab Dispos. 1983; 14:99–110

    CAS  Google Scholar 

  • Veber D, Johnson SR, Cheng HY, Smith BR, Wrad KW, and Kopple KD, Molecular Properties that Influence the Oral Bioavailability of Drug Candidates. J Med Chem 2002; 45:2615–2623

    Article  PubMed  CAS  Google Scholar 

  • Wermuth CG. Designing Prodrugs and Bioprecursors. In: Wermuth CG. Practice of Medicinal Chemistry. London, UK: Academic Press; 1996; pp. 697–715. An earlier version of this paper also appeared in 1984 in Drug Design: Fact or Fantasy by the same publisher

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, Kansas, 66047, USA

    Valentino J. Stella

Authors
  1. Valentino J. Stella
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Kansas, Lawrence, KS, USA

    Valentino J. Stella  & Ronald T. Borchardt  & 

  2. Bristol-Myers Squibb Company, Princeton, NJ, USA

    Michael J. Hageman

  3. Gilead Sciences, Foster City, CA, USA

    Reza Oliyai

  4. Roche Palo Alto, LLC, Palo Alto, CA, USA

    Hans Maag

  5. Hoffmann-La Roche, Inc., Nutley, NJ, USA

    Jefferson W. Tilley

Rights and permissions

Reprints and permissions

Copyright information

© 2007 American Association of Pharmaceutical Scientists

About this chapter

Cite this chapter

Stella, V.J. (2007). A Case for Prodrugs. In: Stella, V.J., Borchardt, R.T., Hageman, M.J., Oliyai, R., Maag, H., Tilley, J.W. (eds) Prodrugs. Biotechnology: Pharmaceutical Aspects, vol V. Springer, New York, NY. https://doi.org/10.1007/978-0-387-49785-3_1

Download citation

Publish with us

Policies and ethics

Societies and partnerships

Search

Navigation